- A NANOSPHERE - HISTONE ACETYLTRANSFERASE (HAT) ACTIVATOR COMPOSITION, PROCESS AND METHODS THEREOF
-
The present disclosure is in relation to a composition comprising nanosphere and histone acetyltransferase (HAT) activator. The disclosed nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide [COMPOUND 1]. The said N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide is covalently conjugated with the carbon nanosphere. The present disclosure further relates to a process for obtaining a composition comprising carbon nanosphere and Histone acetyltransferase (HAT) activator [N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide]. The composition is capable of crossing blood brain barrier and inducing histone acetylation in brain. Further, the composition is capable of increasing neurogenesis, as well as improving long-term memory formation. The said composition thus provides for managing pathological conditions to a subject in need thereof, such as aging- related, neurodegenerative diseases (Alzheimer's in particular), neurological disorders, depression or other kinds of diseases in which increased HAT activity, neurogenesis and/or memory improvement would benefit.
- -
-
-
- Raney nickel-catalyzed hydrogenation of unsaturated carboxylic acids with sodium borohydride in water
-
A mild, selective, and green method for the reduction of unsaturated carboxylic acids with sodium borohydride-Raney nickel (W6) system in water is reported. This method is practical and safe and avoids use of organic solvents. Taylor & Francis Group, LLC.
- Rao, Gopal Krishna,Gowda, Narendra B.,Ramakrishna, Ramesha A.
-
experimental part
p. 893 - 904
(2012/02/01)
-
- ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS
-
The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.
- -
-
Page/Page column 41
(2008/12/07)
-
- Modulators (inhibitors/ activators) of histone acetyltransferases
-
Disclosed are compounds of the formulae: and method of using the compounds to treat cancer, AIDS, HIV infection, and asthma.
- -
-
Page/Page column 4
(2008/06/13)
-
- Quinazolinone inhibitors of cGMP phosphodiesterase
-
Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.
- -
-
-
- Cyclic Nucleotide Phosphodiesterase Inhibition by Imidazopyridines: Analogues of Sulmazole and Isomazole as Inhibitors of the cGMP Specific Phosphodiesterase
-
The synthesis and phosphodiesterase (PDE) inhibitory profile of a series of imidazopyridines, including sulmazole and isomazole, on separated PDE isoenzymes are described.The results show that both sulmazole and isomazole are weak inhibitors of PDE III, and their inotropic activity is unlikely to be due to PDE III inhibition alone.Surprisingly, both compounds were found to be significant inhibitors of the cGMP specific isoenzyme, PDE V, and a series of simple 2-substituted phenylimidazopyridines have been made to investigate the SAR of PDE activity.This has been shown to be sensitive to chain length, polarity, and the nature of the heteroatom linking group.Potent PDE V inhibitors, many of which are also significant inhibitors of PDE IV, have been identified.
- Coates, William J.,Connolly, Brendan,Dhanak, Dashyant,Flynn, Sean T.,Worby, Angela
-
p. 1387 - 1392
(2007/10/02)
-